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Tick transmission of Borrelia spirochetes to humans results in significant morbidity from Lyme 
disease.  Animal studies have demonstrated that transmission of Borrelia from tick vector to the 
mammalian host can be blocked by antibodies against outer surface protein A (OspA). We have 
recently developed borreliacidal human IgG1 monoclonal antibodies (HuMabs) directed against 
OspA.  HuMab 319-44 was borreliacidal against B. burgdorferi (IC50 <1nM), the main cause of 
Lyme disease in North America, and in mice was 100% effective in preventing Borrelia 
transmission after a single dose of 2 mg/kg administered on the day of tick challenge. Since 
passively administered IgG1 antibodies do not have a sufficient half-life to provide protection for 
the 6-7 month peak risk period, we investigated a novel approach of vector-mediated gene 
transfer of HuMabs that could potentially provide protection against Lyme disease during the 
seasonal risk period.  
 
A modified HuMab, 319-44 mod, expressed by a synthetic DNA plasmid (DMAb) was optimized 
and characterized in in vitro OspA binding and bactericidal assays. To assess in vivo protection, 
mice were administered a single DMAb injection into the quadriceps followed by electroporation. 
The mice were then challenged by B. burgdorferi-infected nymphs. Tissue samples were 
monitored by dark-field microscopy for spirochete growth. Serum samples were analyzed by 
ELISA to determine antibody concentrations. 
 
The modified 319-44 DMAb maintained in vitro biological activity comparable to the un-modified 
wild type antibody, and formulation-based delivery of DMAb resulted in long-term expression. 
This led to effective pre-exposure prophylaxis preventing transmission of spirochetes in 80% of 
mice in the murine model of tick-transmitted Lyme disease. These studies represent the first 
demonstration of employing DNA transfer as a rapid, novel delivery system for biologically 
relevant functional full-length HuMAbs in an in vivo animal model and provide support for such 
an approach for pre-exposure immunoprophylaxis to prevent Lyme disease.  
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